Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Vest Financial LLC

Vest Financial LLC increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 59.3% in the 3rd quarter, Holdings Channel.com reports. The firm owned 77,214 shares of the biopharmaceutical company’s stock after acquiring an additional 28,732 shares during the quarter. Vest Financial LLC’s holdings in Regeneron Pharmaceuticals were worth $58,549,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $5,682,636,000. Legal & General Group Plc purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $473,872,000. Bank of New York Mellon Corp purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $472,950,000. Deutsche Bank AG acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $323,249,000. Finally, Man Group plc acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $272,460,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, insider Andrew J. Murphy sold 4,147 shares of the company’s stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the completion of the sale, the insider directly owned 47,833 shares of the company’s stock, valued at $36,960,559.10. This represents a 7.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the sale, the executive vice president directly owned 13,134 shares of the company’s stock, valued at $11,163,900. The trade was a 8.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 8,093 shares of company stock valued at $6,506,845. Company insiders own 6.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on REGN shares. Cantor Fitzgerald increased their target price on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Morgan Stanley boosted their price target on shares of Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 7th. Evercore boosted their price target on shares of Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Leerink Partners upped their price objective on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research note on Monday, August 17th. Finally, UBS Group raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $660.00 to $978.00 in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $846.28.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $805.67 on Thursday. The firm’s fifty day simple moving average is $791.56 and its 200-day simple moving average is $722.18. The stock has a market capitalization of $82.95 billion, a price-to-earnings ratio of 19.91, a PEG ratio of 1.37 and a beta of 0.16. Regeneron Pharmaceuticals, Inc. has a 12 month low of $572.75 and a 12 month high of $859.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. Regeneron Pharmaceuticals’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $12.81 EPS. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 48.87 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a $0.94 dividend. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.